#NewAseBioMember | “AseBio is a key reference entity in the Spanish and European biotechnology sector”

AseBio. What does your company's work bring to the table and what is its strength?

Alejandro Expósito. Our company, a spinoff of the Autonomous University of Madrid (UAM), is dedicated to the research and development of a family of compounds with therapeutic potential. We bring innovation and scientific knowledge to the biotechnology sector, with the aim of developing more effective and safer treatments for diseases that currently have no cure. Our strength lies in our capacity for innovation, in the collaboration with the UAM and the support we have from investors and experts in the pharmaceutical industry, which allows us to access advanced resources and knowledge in biotechnology.

AseBio. What is AseBio for you?

Alejandro Expósito. For us, AseBio is a key reference entity in the Spanish and European biotechnology sector. It represents an invaluable platform that allows us to consolidate our organization through access to knowledge, internationalization, and institutional support. AseBio is a meeting point for companies, institutions, and professionals in the sector, facilitating collaboration and the exchange of ideas.

AseBio. When did you first hear about AseBio?

Alejandro Expósito. I first heard about AseBio around 2017, just when I started working in the pharmaceutical and biotechnology industry. Since then, I have closely followed their work and impact on the sector.

AseBio. What do you expect from being part of an association like AseBio?

Alejandro Expósito. We expect that being part of AseBio will provide us with the opportunity to collaborate with other members, share best practices, promote research and innovation, and establish synergies that drive progress in our specialized areas. Additionally, we seek to increase our visibility and reputation in the biotechnology sector, as well as access new funding and development opportunities.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Alejandro Expósito. The biggest challenge for our company is transforming our research into safe and effective therapeutic solutions that can reach the market and benefit patients. In the biotechnology sector in general, one of the biggest challenges is improving public-private collaboration and technology transfer, as well as industrializing biotechnological developments to generate greater economic and social impact.